501 related articles for article (PubMed ID: 32663575)
1. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
2. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
3. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
5. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
6. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
8. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
9. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system.
Coperchini F; Chiovato L; Croce L; Magri F; Rotondi M
Cytokine Growth Factor Rev; 2020 Jun; 53():25-32. PubMed ID: 32446778
[TBL] [Abstract][Full Text] [Related]
10. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Zhao M
Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2: a storm is raging.
Pedersen SF; Ho YC
J Clin Invest; 2020 May; 130(5):2202-2205. PubMed ID: 32217834
[TBL] [Abstract][Full Text] [Related]
12. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
13. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.
Tufan A; Avanoğlu Güler A; Matucci-Cerinic M
Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202
[TBL] [Abstract][Full Text] [Related]
14. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
15. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
[TBL] [Abstract][Full Text] [Related]
16. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
17. Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19.
Luo W; Li YX; Jiang LJ; Chen Q; Wang T; Ye DW
Trends Pharmacol Sci; 2020 Aug; 41(8):531-543. PubMed ID: 32580895
[TBL] [Abstract][Full Text] [Related]
18. IL-6: Relevance for immunopathology of SARS-CoV-2.
Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
[TBL] [Abstract][Full Text] [Related]
19. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
20. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Liu B; Li M; Zhou Z; Guan X; Xiang Y
J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]